Development

自上次审查以来，癌症研究所有24名新成员：7名翻译人员，8名 基础科学家和九名临床科学家。表7.5.1显示了迄今的招聘情况。而NYUCI机构基金 用来支持这些新招募人员的费用CCSG资金被用来资助 其中许多新人的实验室，并为新的核心提供资金，没有这些核心，这些招聘不会 已经成为可能(例如基因组学设施和siRNA核心)。如第6.0节所述，NYUCI招聘 在上一个供资期间分三个阶段进行。第一阶段的重点是关键新人，包括 重要的癌症焦点，将补充现有的社区。因此，对博士的招聘。 Bhardwaj和O‘Neill扩展了免疫学现有的卓越表现，包括免疫治疗以及 将黑色素瘤添加到我们基于CCSG疾病的计划中，该计划已经包括泌尿生殖系统和乳房 癌症。病理学系主任，David Roth，医学博士，联合项目负责人 免疫学项目为癌症研究所提供了空间，用于早期招募Bhardwaj，Dylacht博士 还有奥尼尔。今年，Bhardwaj博士和Dylacht博士搬进了癌症研究中心， 奥尼尔医生请到疫苗中心。 第二阶段的重点是通过对新兵的具体投资来增加临床计划的深度 这将扩大临床服务和研究能力。临床癌症中心于2004年7月开业， 以及招募以疾病为基础、按计划调整的临床医生(例如，Novik、Axelrod、Tiersten、 钱德拉、斯金纳和其他人)在开业前提供了一个多学科临床环境 从一开始就致力于研究和关怀。目前，NYUCI有12个疾病管理小组。最后，有了 2006年5月，斯米洛研究中心开幕，癌症研究中心的三个研究楼层 开学后，最新的新兵(Dasgupta、Yamasaki、Cho、KRogsgaard、Trombetta)来到校园。 发展基金被指定用于招聘一名临床研究副主任，以建立 临床研究企业和促进跨研究实体的合作，以将实验室结果转化为 该诊所，招聘一名分子流行病学家，在各种项目中衔接研究，并建立一个 合作和互动的流行病学和预防计划。这些优先事项是基于 战略计划的措施和选管会的建议。2005年，威廉·卡罗尔医学博士 被任命为癌症研究所副所长，负责临床研究企业。我们是， 然而，在招募分子流行病学家方面没有成功，2005年，助理罗伊·肖尔博士 流行病学和预防主任在日本担任了一个职位，并努力招聘以填补这一职位 成为我们的首要任务。2006年初，一位候选人正在进行最后的谈判，但决定留在自己的职位上 机构。CI正在积极招聘这两个职位，并正在与以下其中一个职位进行初步谈判 副主任职位的最终候选人；我们的计划是通过实地考察填补这一职位。

Since the previous review, there have been 24 recruits to the Cancer Institute: seven translational, eight basic scientists, and nine clinical. Table 7.5.1 shows recruitments to date. While NYUCI institutional funds were used to support the expense of these recruits CCSG funds were used to fund pilot projects in the laboratories of many of these recruits, and to fund new cores without which these recruitments would not have been possible (e.g. Genomics Facility and siRNA core). As mentioned in Section 6.0 NYUCI recruitment took place in three phases during the last funding period. The first phase focused on key recruits with significant cancer focus that would complement the existing community. Thus the recruitment of Drs. Bhardwaj and O'Neill extended existing excellence in immunology to include immunotherapy as well as adding melanoma to our CCSG disease based programs that already included Genitourinary and Breast Cancer. The Chair of the Department of Pathology, David Roth, MD, PhD, and Co-Program Leader of the Immunology Program loaned the Cancer Institute space for the early recruitments of Drs. Bhardwaj, Dynlacht and O'Neill. This year, Drs. Bhardwaj and Dynlacht have since moved into the Cancer Research Center and Dr. O'Neill to the Vaccine Facility. The second phase focused on increasing depth in the clinical program with specific investments in recruits that would expand clinical services and research capabilities. The Clinical Cancer Center opened July 2004, and recruitment for disease based, programmatically aligned clinicians (e.g. Novik, Axelrod, Tiersten, Chandra, Skinner and others) prior to its opening provided for an environment of multi-disciplinary clinical research and care from its inception. Currently the NYUCI has 12 Disease Management Groups. Finally, with the opening of the Smilow Research Center May 2006, the three research floors of the Cancer Research Center opened and the newest recruits arrived on campus (Dasgupta, Yamasaki, Cho, Krogsgaard, Trombetta). Developmental Funds were earmarked to recruit a Deputy Director for Clinical Research to build the clinical research enterprise and foster collaborations across research entities to translate laboratory findings in the clinic, to recruit a molecular epidemiologist to bridge research within various programs, and build a collaborative and interactive Epidemiology and Prevention Program. These priorities were based upon the initiatives of the Strategic Plan and the recommendations of the EAB. In 2005, William Carroll, MD was named the Deputy Director for the Cancer Institute, responsible for the clinical research enterprise. We were, however, unsuccessful in recruiting a Molecular Epidemiologist, and in 2005, Dr. Roy Shore, the Associate Director for Epidemiology and Prevention took a position in Japan, and recruitment efforts to fill this position became our highest priority. In early 2006, a candidate was in final negotiations, yet decided to stay at his institution. The CI is actively recruiting for both positions and is in preliminary negotiations with one of the final candidates for the Associate Director position; our plan is to have this position filled by the Site Visit.